A detailed examination of China’s increasingly important chemical and pharmaceutical industry. Numerous case studies describe how western companies, such as BASF, Bayer, Bicoll, Ciba, Degussa, DSM and Novartis are managing their market entry in China.
A casebook that discusses all the mega mergers and acquisitions in terms of value, that have happened in different industry sectors such as pharmacy, technology, telecommunications, media and entertainment, electrical and electronics, energy, finance, consumer goods, metals, and automobile and airlines.
The Swiss pharmaceutical industry is world-famous, and of today's top five global pharmaceutical businesses, two are Swiss - Roche and Novartis. Novartis was created in 1996 from a merger between three other major companies, Ciba, Geigy and Sandoz (the merger was the biggest ever in business history worldwide up to that point), but despite being a relatively new name, it is rooted in over 150 years of history. Focusing on the emergence of Novartis, this authoritative book is also the fascinating story of how Switzerland's pharmaceutical industry grew out of early dye-production for textiles in the mid nineteenth century, scored major triumphs with the introduction of products such as DDT and Valium in the twentieth century, and developed into the far-reaching international healthcare providers of today.
Only those who are sure of their origin can know their destination. True to this principle, Anna Bálint for the first time presents the history of Clariant, the globally operating chemical company which was formed by a merger of Sandoz and Hoechst. Eyewitness accounts complete the portrait and give an informative as well as entertaining insight into the demanding task of successfully melding two distinct corporate cultures into a single strong and innovative enterprise.
China has used industrial policies to try to build large corporations that can challenge those based in more advanced countries. By the late 1990s the operational mechanism of China's large firms had seen large advances. Simultaneously, a revolution has taken place in global business systems, and China's large firms are even further behind the global leaders than when they began their reforms. The WTO will require China to operate rapidly on the 'global playing field' in competition with the world's leading corporations, and this increased gap presents a deep challenge for China's business and political leaders. Peter Nolan presents here the first in-depth case studies of China's large corporations under economic reform, combined with systematic benchmarking of these firms against the world's leading corporations. The book is an unrivalled resource of information on Chinese businesses, and also leads the reader to consider the impact of China's response to its current challenges not only on China itself, but on the wider global economy.
The main purpose of the book is to discuss new trends in the dynamic geography of innovation and argue that in an era of increasing globalization, two trends seem quite dominant: rigid territorial models of innovation, and localized configurations of innovative activities. The book brings together scholars who are working on these topics. Rather than focusing on established concepts and theories, the book aims to question narrow explanations, rigid territorializations, and simplistic policy frameworks; it provides evidence that innovation, while not exclusively dependent on regional contexts, can be influenced by place-specific attributes. The book will bring together new empirical and conceptual work by an interdisciplinary group of leading scholars from areas such as economic geography, innovation studies, and political science. Based on recent discussions surrounding innovation systems of different types, it aims to synthesize state-of-the-art know-how and provide new perspectives on the role of innovation and knowledge creation in the global political economy.
The book reviews the history of the formation and success of Ciba, Geigy and Sandoz. The book reviews the acquisitions, joint ventures, mergers and divestitures of Ciba-Geigy and Ciba Specialty Chemi-cals. The result of being a "White Knight" and not doing proper due diligence had dire consequences for the acquir-ing company such as Ciba Specialty Chemicals.
One of the world's leading pharmaceutical companies, the Swiss multinational Novartis traces its history and that of its predecessor companies back to the first dye factories in Basel in the early 19th century. This second edition of the company's history covers early exports and expansion abroad, the unparalleled upsurge of the chemical industry in Basel during the First World War and then the emergence of pharmaceuticals in the interwar years. The enormous challenges of the Second World War were followed by an economic boom in the 1950s and 60s, the merger of CIBA and Geigy, the numerous diversifications in the 1970s and 80s, the merger of Ciba and Sandoz to found Novartis, and finally the first 25 years of Novartis. Those 25 years have included innovations in pharmaceuticals and medicine, and game-changing technologies such as the modification of T-cells. In addition to the running text, fifteen thematic articles outline the company's widely different innovations: from CIBA's early hormone preparations to the outstanding graphic design of Geigy Design, from revolutionary drugs like Sandimmune or Gleevec right through to the Novartis Campus project.
The book reviews current brand and generic business in pharmaceuticals manufacturing practices. Based on examples, the reader can interpolate, extrapolate and exploit mutual behavior of chemicals to design and commercialize processes that fulfill the demands, also considering the minimization of the environmental impact on effluents. Readers will be able to simplify process development, design and commercialize economic manufacturing processes.